Our technology enhances CAR-T cell therapy for solid tumors by overcoming their immunosuppressive environment.
SOCS1 inactivation in CD4+ and CD8+ T cells boosts intratumor accumulation, proliferation, survival, and functionality, promoting tumor rejection.
This results in more effective, durable CAR-T therapies and enables the production of functional off-the-shelf allogenic cells.
